Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 7/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.34 |
| ▸ | MEN1 | O00255 | 2/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | TNKS | O95271 | 1/20 | 0.33 |
| ▸ | PARP1 | P09874 | 1/20 | 0.33 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.33 |
| ▸ | CSNK2B | P67870 | 1/20 | 0.33 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.33 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.33 |
| ▸ | PARP2 | Q9UGN5 | 1/20 | 0.33 |
| ▸ | CDK1 | P06493 | 1/20 | 0.33 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.33 |
| ▸ | SLC18A3 | Q16572 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16233110 | 0.81 | MAPT (0.52) | MAPTKMT2AALDH1A1MEN1KDM4E | |
| SCHEMBL5206947 | 0.75 | IDO1 (0.46) | MAPTKMT2AALDH1A1MEN1KDM4E | |
| SCHEMBL16197340 | 0.74 | CYP1A2 (0.40) | HPGDMAPTKMT2AALDH1A1MEN1 | |
| SCHEMBL5078481 | 0.74 | ALDH1A1 (0.40) | HPGDMAPTKMT2AALDH1A1MEN1 | |
| SCHEMBL16231354 | 0.74 | CDK1 (0.47) | MAPTKMT2AALDH1A1MEN1TNKS | |
| SCHEMBL17367651 | 0.73 | TNKS (0.46) | MAPTKMT2AALDH1A1MEN1HTT | |
| SCHEMBL9798503 | 0.73 | ALDH1A1 (0.34) | HPGDMAPTKMT2AALDH1A1MEN1 | |
| SCHEMBL11068614 | 0.72 | KDM4E (0.49) | HPGDMAPTKMT2AALDH1A1KDM4E | |
| SCHEMBL20828385 | 0.71 | MAPT (0.54) | MAPTKMT2AALDH1A1MEN1KDM4E | |
| SCHEMBL9583765 | 0.70 | KMT2A (0.46) | MAPTKMT2AALDH1A1MEN1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9433608-B2 | Compositions and method for treatment of ischemic neuronal reperfusion injury | HOWARD UNIVERSITY (US) | 2016-09-06 | — | — | US | disclosed |
| US-9248118-B2 | Compositions and method for treatment of ischemic neuronal reperfusion injury | HOWARD UNIVERSITY (US) | 2016-02-02 | — | — | US | disclosed |
| US-8993512-B2 | Compositions and method for treatment of ischemic neuronal reperfusion injury | HOWARD UNIVERSITY (US) | 2015-03-31 | — | — | US | disclosed |
| US-20140336120-A1 | Compositions And Method For Treatment Of Ischemic Neuronal Reperfusion Injury | HOWARD UNIVERSITY (US) | 2014-11-13 | — | — | US | disclosed |
| US-20140336183-A1 | Compositions And Method For Treatment Of Ischemic Neuronal Reperfusion Injury | HOWARD UNIVERSITY | 2014-11-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140336120-A1 | Compositions And Method For Treatment Of Ischemic Neuronal Reperfusion Injury | BDNF, GAP43, BAX | HPGD 1970/4885MAPT 503/4885KMT2A 4472/4885 |
| US-20140336183-A1 | Compositions And Method For Treatment Of Ischemic Neuronal Reperfusion Injury | GRIN3A, GRIN3B, GRIK3 | HPGD 1455/4885MAPT 1504/4885KMT2A 3827/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.